Precautions for dienogest

German pharmaceutical giant Bayer announced that its new gynecological drug dienogest has been approved by Chinese regulatory authorities for the treatment of endometriosis (EMs). It is a once-daily oral tablet containing 2 mg of dienogest, specifically used to treat EMs, a chronic gynecological disease. Today let’s take a closer look at the precautions for dienogest.

1. Changes in bleeding patterns: Most patients treated with dienogest tablets experienced changes in menstrual bleeding patterns.

2. The increased risk of thromboembolism during the puerperium must be considered.

3. If symptoms of arterial or venous thrombosis are present or suspected, treatment should be stopped immediately.

4. Cancer: A meta-analysis of 54 epidemiological studies reported that women currently using oral contraceptives (OCs) (mainly estrogen and progestin combination preparations) have a slightly increased relative risk of breast cancer.

5. Circulatory disease: Based on epidemiological studies, there is little evidence of an association between single progestin preparations and an increased risk of myocardial infarction or cerebral thromboembolism. However, the risk of cardiovascular and cerebrovascular events is significantly associated with increasing age, hypertension, and smoking. In women with high blood pressure, progestin-only medications may slightly increase the risk of stroke.

6. Severe uterine bleeding: For example, in women with adenomyosis or uterine leiomyomas, uterine bleeding may be worsened while using dienogest tablets. If the bleeding is large or continuous, it may lead to anemia (severe anemia occurs in some cases). In the event of anemia, discontinuation of dienogest tablets should be considered.

7. Some studies have shown that the use of a single progestin drug has a slightly increased risk of venous thromboembolism (deep vein thrombosis, pulmonary embolism), but the increase is not statistically significant. It is generally believed that risk factors for venous thromboembolism (VTE) include: a personal or family history of a sibling or parent who developed VTE at a relatively young age, age, obesity, long-term immobilization, major surgery, or severe trauma. In the case of long-term immobilization, it is best to stop using dienogest tablets (if elective surgery is to be performed, stop taking the medicine at least 4 weeks in advance), and resume use after 2 weeks of complete reactivation.

It is a new type of selective progesterone receptor agonist that can inhibit ovarian function and endometrial cell proliferation, thereby reducing the pain associated with EMs and shrinking and shrinking the lesions.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.